Clinical and microbiological effects of azithromycin in the treatment of generalized chronic periodontitis: a randomized placebo-controlled clinical trial.
Author(s): Sampaio E, Rocha M, Figueiredo LC, Faveri M, Duarte PM, Gomes Lira EA, Feres M
Affiliation(s): Department of Periodontology, Dental Research Division, Guarulhos University, Guarulhos, Sao Paulo, Brazil.
Publication date & source: 2011-09, J Clin Periodontol., 38(9):838-46. Epub 2011 Jul 19.
Publication type: Research Support, Non-U.S. Gov't
AIM: To evaluate the effects of systemic azithromycin (AZM) as an adjunct to scaling and root planing (SRP) in the treatment of generalized chronic periodontitis (ChP). METHODS: Forty subjects were randomly assigned to receive SRP alone or combined with AZM (500 mg/day) for 5 days (n=20/group). Clinical and microbiological examinations were performed at baseline, 6 months and 1-year post-SRP. Nine plaque samples per subject were analysed by checkerboard DNA-DNA hybridization for 40 bacterial species. Differences between groups were assessed using the Mann-Whitney test and over time using Friedman and Dunn's tests. RESULTS: No statistically significant differences were observed between groups for any parameters evaluated at 1-year post-treatments. Both therapies equally reduced the mean probing depth (PD) (SRP: 3.83 +/- 1.92, AZM: 3.45 +/- 1.74) and improved the mean clinical attachment (SRP: 2.35 +/- 1.70, AZM: 2.68 +/- 1.76) in sites with initial PD7 mm (primary outcome variable) between baseline and 1 year. The mean counts and proportions of several periodontal pathogens were reduced, and those of host-beneficial species were increased after treatments. Nonetheless, an important recolonization with red complex species was observed in both groups over the course of the study. CONCLUSION: The data of the present study suggest no adjunctive benefit of AZM in the treatment of generalized ChP. (c) 2011 John Wiley & Sons A/S.